IL28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C.

Détails

ID Serval
serval:BIB_8DC18195A6BE
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
IL28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C.
Périodique
Alimentary Pharmacology and Therapeutics
Auteur(s)
Fattovich G., Covolo L., Bibert S., Askarieh G., Lagging M., Clément S., Malerba G., Pasino M., Guido M., Puoti M., Gaeta G.B., Santantonio T., Raimondo G., Bruno R., Bochud P.Y., Donato F., Negro F.
Collaborateur(s)
on behalf of the ITAHEC Study Group
ISSN
1365-2036 (Electronic)
ISSN-L
0269-2813
Statut éditorial
Publié
Date de publication
2011
Volume
33
Numéro
10
Pages
1162-1172
Langue
anglais
Résumé
Aliment Pharmacol Ther 2011; 33: 1162-1172 SUMMARY: Background  Hepatitis C virus (HCV) is a major cause of chronic liver disease, cirrhosis and hepatocellular carcinoma and the identification of the predictors of response to antiviral therapy is an important clinical issue. Aim  To determine the independent contribution of factors including IL28B polymorphisms, IFN-gamma inducible protein-10 (IP-10) levels and the homeostasis model assessment of insulin resistance (HOMA-IR) score in predicting response to therapy in chronic hepatitis C (CHC). Methods  Multivariate analysis of factors predicting rapid (RVR) and sustained (SVR) virological response in 280 consecutive, treatment-naive CHC patients treated with peginterferon alpha and ribavirin in a prospective multicentre study. Results  Independent predictors of RVR were HCV RNA <400 000 IU/mL (OR 11.37; 95% CI 3.03-42.6), rs12980275 AA (OR 7.09; 1.97-25.56) and IP-10 (OR 0.04; 0.003-0.56) in HCV genotype 1 patients and lower baseline γ-glutamyl-transferase levels (OR = 0.02; 0.0009-0.31) in HCV genotype 3 patients. Independent predictors of SVR were rs12980275 AA (OR 9.68; 3.44-27.18), age <40 years (OR = 4.79; 1.50-15.34) and HCV RNA <400 000 IU/mL (OR 2.74; 1.03-7.27) in HCV genotype 1 patients and rs12980275 AA (OR = 6.26; 1.98-19.74) and age <40 years (OR 5.37; 1.54-18.75) in the 88 HCV genotype 1 patients without a RVR. RVR was by itself predictive of SVR in HCV genotype 1 patients (OR 33.0; 4.06-268.32) and the only independent predictor of SVR in HCV genotype 2 (OR 9.0, 1.72-46.99) or genotype 3 patients (OR 7.8, 1.43-42.67). Conclusions  In HCV genotype 1 patients, IL28B polymorphisms, HCV RNA load and IP-10 independently predict RVR. The combination of IL28B polymorphisms, HCV RNA level and age may yield more accurate pre-treatment prediction of SVR. HOMA-IR score is not associated with viral response.
Pubmed
Web of science
Open Access
Oui
Création de la notice
06/05/2011 13:42
Dernière modification de la notice
08/05/2019 21:50
Données d'usage